US 12,168,047 B2
Tuberculosis antigen cassettes
Dominick Laddy, New York, NY (US); Danilo Casimiro, New York, NY (US); Thomas Evans, New York, NY (US); Megan Fitzpatrick Forrest, New York, NY (US); and Nathalie Cadieux, New York, NY (US)
Assigned to International AIDS Vaccine Initiative, Inc., New York, NY (US)
Filed by International AIDS Vaccine Initiative, Inc., New York, NY (US)
Filed on Mar. 16, 2023, as Appl. No. 18/184,869.
Application 18/184,869 is a continuation of application No. 16/756,206, granted, now 11,638,749, previously published as PCT/US2018/055817, filed on Oct. 15, 2018.
Claims priority of provisional application 62/573,432, filed on Oct. 17, 2017.
Prior Publication US 2023/0270834 A1, Aug. 31, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/04 (2006.01); C07K 14/35 (2006.01)
CPC A61K 39/04 (2013.01) [C07K 14/35 (2013.01); C07K 2319/00 (2013.01)] 7 Claims
 
1. A method of eliciting an immune response against Mycobacterium tuberculosis in a mammal comprising administering to the mammal an immunologically sufficient amount of a fusion protein comprising at least three Mtb PPE antigens chosen from Rv3873, Rv1387, Rv3892c, Rv1789, Rv1800, and Rv1039c, wherein: Rv3873 comprises the amino acid sequence set forth in SEQ ID NO:19, Rv1387 comprises the amino acid sequence set forth in SEQ ID NO: 21, Rv3892c comprises the amino acid sequence set forth in SEQ ID NO:23, Rv1789 comprises the amino acid sequence set forth in SEQ ID NO:25, Rv1800 comprises the amino acid sequence set forth in SEQ ID NO:27, and/or Rv1039c comprises the amino acid sequence set forth in SEQ ID NO:29.